Your AI-Trained Oncology Knowledge Connection!
As the COVID-19 pandemic beats down on major cities like New York, oncologists across the United States are either bracing themselves for what will hopefully be a peak in cases or desperately preparing for when the storm will hit their own health systems.
The phase III ADAURA trial of adjuvant osimertinib in patients with EGFR mutation–positive non–small cell lung cancer has been unblinded due to “overwhelming efficacy.”
Join top leaders in the lung cancer field as they share their insights on COVID-19 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system on Thursday, May 14, 2020 at 8 PM EST.
Shilpa Gupta, MD, discusses the modifications made to patient care in light of the COVID-19 pandemic, the hurdles faced with clinical trials during this time, and some of the ways in which her institution is facing the virus-related challenges head-on.
Jason J. Luke, MD, FACP, discusses the future of T-cell therapies in melanoma, emerging biomarkers, and ongoing research regarding the gut microbiome.
This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.
Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.
Ivosidenib showed minimal toxicity, substantial 2-hydroxyglutarate reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone.
Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.
Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.
Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.
The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.
This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.
Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.
STP705 met the primary efficacy end point in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ.
The NCCN has published guidelines for ensuring that patients with cancer, care providers, and staff are kept as safe as possible during the COVID-19 crisis.
An increased proportion of Indigenous American genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer.
Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the impact of the COVID-19 outbreak on Hong Kong and explained how the implementation of early preventive safety measures may have contributed to the low incidence rate.
A supplemental Biologics License Application has been filed with the FDA for avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.
The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.
The investigational RAF inhibitor lifirafenib demonstrated antitumor activity in patients with melanoma and other solid tumors.
Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.
Florida Cancer Specialists & Research Institute recently launched telehealth services across all Florida Cancer Specialists & Research Institute sites statewide, allowing patients continued and convenient access to care, while mitigating the impact and spread of COVID-19.
AV-GBM-1 showed early promise in an interim overall survival analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma.
Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.
When the first case of coronavirus disease 2019 was diagnosed in Washington on January 20, 2020 clinicians at Seattle Cancer Care Alliance decided to act expeditiously and unhesitatingly to minimize disease spread.
The FDA has granted a priority review designation to nivolumab plus ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.
Treatment with paxalisib, an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival signal in patients with glioblastoma.
The FDA has granted the PD-1 inhibitor balstilimab a Fast Track Designation for the treatment of patients with cervical cancer.